This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

The Debate Continues

Gerald W. Chodak, MD

JAMA. 1994;272(10):813-814.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recently, increasing attention has focused on screening asymptomatic men for prostate cancer. Factors driving this initiative include the low percentage of localized cancers diagnosed by conventional methods, the inability to cure advanced disease, and the development of serum prostate-specific antigen (PSA) assay, which improves early detection. Unlike screening for breast cancer, however, no controlled studies have demonstrated that screening for prostate cancer reduces mortality or increases life expectancy. Until the National Institutes of Health—sponsored randomized screening trial is completed, some guidance is needed in making decisions regarding routine testing.

See also p 773.

The article by Krahn et al¹ in this issue of THE JOURNAL is the first study published using a Markov model to predict the outcomes from screening using PSA. Performing a one-time screen using digital rectal examination and PSA is predicted to increase life expectancy by 0.6 and 1.7 days for 50-and 70-year-old men, respectively. However, . . . [Full Text PDF of this Article]

Author Affiliations
From the Prostate and Urology Center, Louis A. Weiss Memorial Hospital, the University of Chicago Hospitals, Chicago, III.

Footnotes
Reprint requests to the Prostate and Urology Center, Louis A. Weiss Memorial Hospital, 4646 N Marine Dr, Chicago, IL 60640 (Dr Chodak).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?